Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study
Learn more about the PHERGain study in this plain language summary published in Future Oncology.
Read the full article here.
The original article on which this summary is based is called ‘Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial’ and was originally published in the journal The Lancet Oncology. The original article can be read here.